Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAncer preventive and Pleiotropic TherApy IN smokers with COPD (ATORVASTATIN)
2024-516714-37-00Phase 3Authorised
- Sponsor
- Medical University of Białystok
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Atoris 40 mg with Placebo (2 arms). Primary endpoints: Exacerbation rate and Time to exacerbation. Planned start Dec 2024; status: authorised.
02
Drugs
atorvastatin
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2024-516714-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516714-37-00.